Tech Company Financing Transactions

KemPharm Funding Round

DeWaay Capital Management and private investors participated in a $3.8 million Series B capital raise for KemPharm. The round was announced by the company on 9/16/2009.

Transaction Overview

Company Name
Announced On
9/16/2009
Transaction Type
Venture Equity
Amount
$3,800,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1180 Celebration Blvd. 103
Celebration, FL 34747
USA
Email Address
Overview
KemPharm, Inc. is an early phase biopharmaceutical company located in the Iowa City, IA area near the campus of the University of Iowa. We are focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.
Profile
KemPharm LinkedIn Company Profile
Social Media
KemPharm Company Twitter Account
Company News
KemPharm News
Facebook
KemPharm on Facebook
YouTube
KemPharm on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Travis Mickle
  Travis Mickle LinkedIn Profile  Travis Mickle Twitter Account  Travis Mickle News  Travis Mickle on Facebook
Chief Financial Officer
LaDuane Clifton
  LaDuane Clifton LinkedIn Profile  LaDuane Clifton Twitter Account  LaDuane Clifton News  LaDuane Clifton on Facebook
Vice President
Rene Braeckman
  Rene Braeckman LinkedIn Profile  Rene Braeckman Twitter Account  Rene Braeckman News  Rene Braeckman on Facebook
VP - Bus. Development
Gordon Johnson
  Gordon Johnson LinkedIn Profile  Gordon Johnson Twitter Account  Gordon Johnson News  Gordon Johnson on Facebook
VP - Manufacturing
Christopher Lauderback
  Christopher Lauderback LinkedIn Profile  Christopher Lauderback Twitter Account  Christopher Lauderback News  Christopher Lauderback on Facebook
VP - Operations
Christal Mickle
  Christal Mickle LinkedIn Profile  Christal Mickle Twitter Account  Christal Mickle News  Christal Mickle on Facebook
VP - R & D
Sven Guenther
  Sven Guenther LinkedIn Profile  Sven Guenther Twitter Account  Sven Guenther News  Sven Guenther on Facebook
VP - Regulatory Affairs
Andrew Barrett
  Andrew Barrett LinkedIn Profile  Andrew Barrett Twitter Account  Andrew Barrett News  Andrew Barrett on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/16/2009: 3PrimiR venture capital transaction
Next: 9/16/2009: DayLife venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary